Gastroenteropancreatic Neuroendocrine Tumors Market to Surge Strongly by 2035 – BIS Research

What are Gastroenteropancreatic Neuroendocrine Tumors? 

GEP-NETs are rare tumors of the gastrointestinal tract and pancreas, originating from hormone-producing endocrine cells. They can be functional (hormone-secreting) or non-functional, often diagnosed late due to nonspecific symptoms. Treatment approaches include surgery, somatostatin analogues, chemotherapy, targeted therapies, and PRRT. The recent integration of immunotherapy and biomarker-driven approaches is opening new avenues for personalized care. 

What is the Current Market Outlook for Gastroenteropancreatic Neuroendocrine Tumors? 

The GEP-NETs market outlook is promising, with North America leading due to higher incidence reporting, advanced diagnostic infrastructure, and access to novel therapies such as Lutathera (PRRT). Europe follows with strong clinical adoption of somatostatin analogues and PRRT, while Asia-Pacific is expected to grow rapidly due to improved healthcare access and rising awareness. Challenges include high treatment costs, complex diagnostics, and limited clinical expertise in underserved regions. However, growing R&D pipelines and supportive regulatory approvals are expected to overcome these barriers. 

What is the key Innovation & Trends in Gastroenteropancreatic Neuroendocrine Tumors Market? 

• Adoption of Gallium-68 DOTATATE PET/CT imaging for earlier and more accurate diagnosis 
• Expansion of PRRT (e.g., Lutathera) as a frontline therapy option with improved safety profiles 
• Development of next-generation somatostatin analogues with longer action and fewer side effects 
• Ongoing trials for tyrosine kinase inhibitors (TKIs) and immunotherapies to expand treatment scope 
• Increasing focus on biomarker-driven precision medicine for tailored treatment approaches 
• Collaborations between pharma and academic institutions to accelerate innovation 

How Does This Report Help Organizations Drive Strategic Growth? 

• Benchmark therapies – Compare somatostatin analogues, PRRT, chemotherapy, and targeted therapies. 
• Evaluate innovation pipelines – Track clinical trials in TKIs, PRRT combinations, and immunotherapies. 
• Identify regional opportunities – Assess growth prospects in North America, Europe, and Asia-Pacific. 
• Monitor competitive strategies – Review partnerships, licensing deals, and biomarker-focused R&D. 
• Navigate challenges – Address high therapy costs, regulatory hurdles, and limited expertise. 

Explore Full TOC or Book a Preview  

What Are the Demand Driver and Challenges in Gastroenteropancreatic Neuroendocrine Tumors Market? 

Demand Drivers: 

• Rising incidence of GEP-NETs worldwide 
• Advances in diagnostics (PET/CT scans) enabling earlier detection 
• Approvals of novel therapies (PRRT, targeted agents) 
• Growing awareness among patients and clinicians 
• Increased R&D investment in rare tumor drug pipelines 

Challenges: 

• High treatment costs limiting access in low-resource regions 
• Complex diagnostics often leading to late-stage detection 
• Limited clinical expertise in rare cancers 
• Regulatory delays affecting therapy availability 

What is the Market Segmentation in the Gastroenteropancreatic Neuroendocrine Tumors Market? 

By Drug Class 

•    Chemotherapy 

•    Peptide Receptor Radionuclide Therapy (PRRT) 

•    Somatostatin Analogues 

•    Targeted Therapies 

By Route of Administration 

•    Injectable 

•    Intra tumoral 

•    Oral 

By Region 

 o    North America 

o    Europe  

o    Asia-Pacific 

What Is the Competitive Landscape in the Gastroenteropancreatic Neuroendocrine Tumors Market? 

Strategic Initiatives 

Leading pharma companies are advancing their GEP-NET portfolios through approvals, partnerships, and acquisitions. Novartis has strengthened its position with Lutathera (PRRT) and Sandostatin, while investing in biomarker-driven trials to expand indications. Ipsen continues to grow Somatuline’s market presence, securing approvals in additional regions and forming alliances with academic centers for expanded real-world evidence programs. Roche is exploring next-generation targeted therapies and immunotherapies through collaborations with biotech firms. Meanwhile, emerging players are focusing on next-gen PRRT combinations and novel TKIs, often partnering with universities and cancer institutes to accelerate innovation. 

Here Are Some Case Studies and Success Stories in Gastroenteropancreatic Neuroendocrine Tumors Market 

• In the U.S., Lutathera (Novartis) became the first FDA-approved PRRT for GEP-NETs, with real-world data showing improved progression-free survival and reduced hospitalization rates, driving strong adoption across major oncology centers. 
• A European multi-center study validated the effectiveness of Somatuline (Ipsen) in controlling tumor growth and hormone-related symptoms in functional GEP-NETs, reinforcing its role as a frontline therapy. 
• In Japan, collaborative research between academic hospitals and Novartis expanded PRRT applications in pancreatic NETs, improving outcomes in late-stage patients with limited options. 
• A biotech–academic partnership in the U.K. is testing immunotherapy combinations for GEP-NETs, marking a step toward integrating checkpoint inhibitors into rare tumor treatment strategies. 

[Schedule a Call with Industry Experts] 

[Download Complete TOC] 

Related Reports from BIS Research 

Canada Laparoscopy Devices Market                   

Gastrointestinal Endoscopy Market             

Acute Pancreatitis Market                    

About BIS Research 

BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends, which can disrupt the market dynamics in the near future. We publish over 200 market intelligence studies annually, focusing on several deep technology verticals.   

Our strategic market analysis emphasizes market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.    

BIS Research offers syndicate and custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscapes.   

Contact 

Head of Marketing   

Email: media@bisresearch.com    

BIS Research Inc.   

39111 PASEO PADRE PKWY STE 313,   

FREMONT, CA 94538-1686   

Visit our Blog @https://bisresearch.com/insights   

Get Expert Insights @https://community.insightmonk.com    

Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research    

Connect with us on Twitter@ https://twitter.com/BISResearch 

Connect with us on Medium@ https://medium.com/@faisal.bis 

Connect with us on YouTube@ https://www.youtube.com/@BISResearchInc